ERK3 may help prevent mutant p53-initiated tumour development.
We at Novus Biologicals have a wide range of MAPK reagents on our antibody database. MAPKs, or mitogen-activated protein kinases, act as integration points for multiple signalling pathways, and are essential to a wide range of cellular processes. These include differentiation, transcription regulation, growth and proliferation.
We at Novus Biologicals have a wide range of MAPK reagents on our antibody database. MAPKs, or mitogen-activated protein kinases, act as integration points for multiple signalling pathways, and are essential to a wide range of cellular processes. These include differentiation, transcription regulation, growth and proliferation. They are activated via phosphorylation cascades. ERKs, or extracellular signal-regulated kinases, are a part of this group.
Each MAPK gene encodes a particular protein. For example, the MAPK6 antibody is specific to a protein of the Ser/Thr protein kinase family. MAPK 11, meanwhile, encodes to a kinase that is closely related to the p38 MAP kinase. Both can be activated by cellular and environmental stress. The MAPK 11 kinase is activated through phosphorylation by MAP kinase kinases (MKKs), particularly MKK6.
Cellular function can be affected by mutation of proteins involved with MAPK regulation. The transcription factor p53 is the most widely studied, and is known to play a major role in the cellular response to DNA damage. When activated, it can initiate either DNA repair or apoptosis. It has been shown to be the most prolific type of genetic mutation in several major tumours. In vivo, it is phosphorylated by several MAP Kinases. p53 antibodies are widely used in MAPK studies involving cancer cell lines.
ERK3 kinase, alternatively known as PRKM6 and p97MAPK, is part of the MAPK6 pathway. It is activated by cellular damage due to inhibition of the proteasome pathway – a factor in the development of certain tumour cells. Upon activation, it localises to the nucleus. The upregulation of ERK 3 is dependent upon activation of the p38 pathway, but independent of p53, Bcl2 and caspase 3 activity – all of which have been implicated in tumour development. This suggests ERK3 has an intracellular defence role, and may help prevent the development of tumours.
The Article is written by novusbio.com/ providing
http://www.novusbio.com/